Vitiligo on the Face vs. the Hands: Does UV Therapy Work Differently by Location?

Introduction

If you have vitiligo on your face and also on your hands, you may have noticed something puzzling: the patches on your face seem to respond to treatment, while the ones on your fingers barely budge. Or your dermatologist keeps adjusting the dose differently for different areas. This is not guesswork — it reflects a well-documented clinical reality.

UV phototherapy does not work uniformly across the body. Response rates, session frequency, and the time it takes to see repigmentation differ significantly depending on where the vitiligo lesion is located. Understanding why this happens — and what it means for your treatment — can make the difference between staying motivated through a long course of therapy and giving up too soon.

This article explains the science behind body-site variation in vitiligo response, what the research says, and how to set realistic expectations for face, hands, trunk, and other commonly affected locations.

Why Location Matters: The Biology Behind Site Variation

To understand why some areas respond better than others, it helps to understand what UV therapy is actually trying to do.

In vitiligo, melanocytes — the cells responsible for producing skin pigment — are destroyed or become inactive in affected patches. UV therapy, particularly 308nm excimer light and 311nm NB-UVB, works by stimulating the remaining melanocytes at the edge of the lesion and in the hair follicles within the depigmented patch to migrate inward and repopulate the skin.

The key word here is remaining. The success of UV therapy depends heavily on how many functional melanocytes survive in and around the lesion, and this varies significantly by body site. Three biological factors drive this variation:

Melanocyte reservoir density. Melanocytes that survive in vitiligo patches are primarily found in the outer root sheath of hair follicles. Areas with dense, pigmented hair follicles — like the scalp, face, and trunk — have a richer melanocyte reservoir for therapy to draw from. Areas with few or fine follicles — like the fingertips, palms, lips, and the skin over bony prominences — have almost no follicular reservoir, making repigmentation far more difficult to achieve.

Blood supply and UV penetration. Facial skin is highly vascularised, which supports the migration and proliferation of melanocytes. The skin over the dorsal hands and fingers is thicker in terms of UV-blocking layers, and the palmar and plantar skin is the thickest in the body — requiring significantly higher doses to achieve the same biological effect.

Nerve fibre density. There is growing evidence that neuropeptides released by cutaneous nerve fibres play a role in melanocyte survival and migration. The face, particularly around the eyes and mouth, is richly innervated — which may contribute to its relatively better response to UV therapy.

The Face: Where Vitiligo Responds Best

The face is widely regarded as the most treatment-responsive location for vitiligo. Multiple clinical studies and large case series consistently show the highest rates of repigmentation in facial lesions, particularly around the eyes (periorbital), mouth (perioral), and forehead.

Why the face responds well:

• High density of pigmented hair follicles acting as a melanocyte source

• Rich blood supply supporting cell migration

• Thinner stratum corneum allowing deeper UV penetration at lower doses

• Strong innervation supporting neuropeptide-mediated melanocyte activity

What the research says: Studies using 308nm excimer therapy for facial vitiligo consistently report repigmentation rates of 70–90% in periorbital and perioral lesions after 20–30 sessions. A widely referenced study published in the Journal of the American Academy of Dermatology found that facial lesions achieved greater than 75% repigmentation in the majority of patients within 3–4 months of excimer therapy at 3 sessions per week.

Session frequency for the face: 3 sessions per week is standard. Because facial skin is more UV-sensitive, starting doses must be conservative — typically 50–60% of MED for the face, compared to 70% for the trunk. The periorbital area in particular requires careful dose reduction (30–40% below trunk dose) due to the extreme sensitivity of eyelid skin.

Realistic timeline: Most patients with facial vitiligo see initial signs of repigmentation — small pigmented dots appearing within the patch — within 6–10 weeks of consistent therapy. Significant cosmetic improvement is typically visible by 3–6 months.

Patient note: Repigmentation on the face often begins as small dark dots within the white patch. This is normal and a good sign — those dots are melanocytes migrating out of the hair follicles. Over successive sessions, they expand and eventually merge to cover the patch.

The Hands: Where Vitiligo Is Hardest to Treat

If the face represents the optimistic end of vitiligo treatment, the hands — particularly the fingers, knuckles, and fingertips — represent the most challenging. Dermatologists are candid about this with their patients, and the research backs it up.

Why the hands respond poorly:

• Very low density of pigmented hair follicles, especially on the fingers and fingertips

• Thicker skin on the dorsal surface limits UV penetration

• Palmar and fingertip skin is the thickest in the body — requires much higher doses for any biological effect

• Poor vascularisation of distal fingertip skin

• Constant mechanical trauma (hand-washing, friction) disrupts fragile, newly forming melanocytes

• The Koebner phenomenon — whereby trauma or friction triggers new vitiligo lesions — is particularly active on the hands

What the research says: Response rates for acral vitiligo (hands, feet, fingers, toes) are substantially lower than for facial vitiligo. Studies report meaningful repigmentation in only 20–40% of acral lesions, and complete repigmentation is rare. A review in Pigment Cell & Melanoma Research noted that acral sites are the most treatment-resistant locations in vitiligo, with many patients achieving only partial and cosmetically limited improvement even after prolonged therapy.

Session frequency for the hands: 3–5 sessions per week, with significantly higher doses than the face. Dorsal hand doses typically run 10–15% lower than trunk doses, but fingertip and palmar doses may need to be 2–3 times the trunk dose to achieve any therapeutic effect — a level that must be escalated to very gradually to avoid burns.

Realistic timeline: Even with optimal therapy, improvement in hand vitiligo is slow. Patients should not expect to see meaningful change in 3 months. A realistic minimum course is 6–12 months of consistent treatment, with outcomes ranging from partial improvement to minimal response depending on the extent of follicular reservoir loss.

Patient note: If your patches on the hands are not responding as well as patches elsewhere on your body, this is not a sign that your treatment is failing. It reflects the biology of the location. Your dermatologist may recommend continuing face and trunk treatment while taking a more measured approach to the hands.

Other Body Sites: What to Expect

Trunk and limbs (moderate response) The trunk — chest, back, abdomen — and upper arms represent a middle ground. Response rates are lower than the face but considerably better than the hands. Follicular density is moderate, and the skin is accessible and relatively uniform in thickness. Repigmentation rates of 50–70% are commonly reported in trunk and limb lesions after 6 months of consistent therapy. Starting dose is typically 70% MED, with standard escalation.

Scalp (good response, complex to treat) The scalp has an excellent melanocyte reservoir thanks to its dense hair follicles, and when vitiligo affects the scalp, UV therapy can be effective. The challenge is practical: accessing the scalp through hair requires a reduction tip or parting the hair carefully. Response rates are comparable to facial vitiligo, but treatment logistics are more complex.

Neck (good response, dose caution needed) The neck responds well — similar to the face — due to good vascularity and follicular density. However, the skin is sensitive. Dose should be reduced by approximately 20% relative to the trunk dose to avoid erythema.

Lips (poor response) Lip vitiligo (mucosal vitiligo) is among the most resistant to treatment. The vermillion border of the lip has virtually no hair follicles, which means no follicular melanocyte reservoir. Some response may occur from perilesional repigmentation at the lip border, but complete repigmentation of mucosal lip patches is rarely achieved with UV therapy alone. Surgical options (melanocyte transplantation) are often discussed for lip vitiligo that has been stable for at least 2 years.

Around joints — elbows, knees, ankles (poor response) Skin over bony prominences tends to respond poorly. The combination of thicker skin, reduced vascularity, and increased mechanical stress makes these sites similar to acral vitiligo in their resistance. Koebner phenomenon is also active at joint sites.

Side-by-Side: Response Rates by Body Site

Dosing Differently for Different Sites: A Practical Guide

Because UV sensitivity and skin thickness vary so dramatically across the body, dermatologists cannot apply a single dose protocol to all locations simultaneously. Here is how site-specific dosing works in practice:

For patients with lesions across multiple locations, MED testing ideally should be conducted at each major treatment site — not just on a single reference area like the inner forearm. The MED on facial skin can be 30–50% lower than on trunk skin, and the MED on palmar skin may be 2–4 times higher.

When treating multiple sites in one session, the device must be repositioned and the dose adjusted for each site. This is where a flexible handpiece device with multiple reduction tips is practically essential — it allows the clinician or the patient at home to apply the correct dose to the face, then the hands, then the trunk, without applying a uniform exposure that under-treats some areas and burns others.

The importance of real dosimetry here: Site-specific dosing is only reliable if the device is delivering exactly what is prescribed. A timer-based device cannot account for lamp degradation — so while the prescribed dose for the face might be 100 mJ/cm² and the hands 250 mJ/cm², as the lamp ages, both sites are progressively under-dosed with no indication to the patient. Devices with built-in dosimetry correct for lamp output automatically, ensuring each site receives precisely the prescribed dose at every session.

Combining Locations in a Treatment Plan: What Your Dermatologist Should Tell You

If you have vitiligo on both responsive and resistant sites, a well-constructed treatment plan should address this explicitly. Here is what a realistic multi-site plan looks like:

Prioritise the face first. Given the high response rates and the significant cosmetic and psychological impact of facial vitiligo, most dermatologists prioritise facial lesions in the early months of treatment. This also allows the patient to see tangible progress, which supports long-term adherence.

Set honest expectations for the hands early. Patients who are not told about the lower response rates for acral vitiligo often interpret the slow progress on their hands as overall treatment failure and abandon therapy — including for sites like the face where they are actually responding well. Early, transparent communication about site-specific prognosis is essential.

Maintain consistent treatment across all sites. Even if hand lesions are responding slowly, continuing treatment maintains whatever partial repigmentation has been achieved and may support longer-term incremental improvement.

Consider the psychological dimension. Research consistently shows that facial vitiligo carries the highest psychological burden — it is the most visible and the most frequently the cause of social distress. The good news is that it is also the most treatable. For patients who are managing vitiligo across multiple sites, seeing the face respond well can provide meaningful quality-of-life improvement even if the hands remain challenging.

What to Track During Treatment

Regardless of which site you are treating, systematic tracking of repigmentation over time is one of the most important things both patients and clinicians can do. Repigmentation is slow and incremental — changes that are significant over three months are often imperceptible week to week. Without photographs, patients frequently underestimate their progress.

At each session, photograph the treatment site in the same position, same lighting, same distance. A standardised photo protocol — standing at arm's length from a mirror, in daylight, without flash — is adequate for home tracking. The UVThera app automates this, prompting a photo at each session and layering them into a visual timeline.

At weeks 12 and 24, compare photographs formally with your dermatologist. This is when protocol adjustments — dose escalation, frequency changes, or decisions to continue versus discontinue — should be made on the basis of documented evidence rather than impression.

Summary

• The face — particularly around the eyes and mouth — responds best to UV therapy for vitiligo, with repigmentation rates of 70–90% and a realistic timeline of 3–6 months.

• The hands, fingers, and other acral sites are the most treatment-resistant locations, with response rates of 20–40% and timelines of 12–24 months even with optimal therapy.

• The underlying reason is biology: follicular melanocyte density, skin thickness, vascularity, and UV penetration all vary dramatically by body site.

• Dosing must be adjusted by site — the dose appropriate for the face can cause burns on acral skin if applied there, and vice versa.

• Multi-site vitiligo requires a layered treatment plan with site-specific MED values, dose protocols, and realistic outcome expectations communicated clearly from the start.

• Tracking progress through regular standardised photography is essential, because repigmentation is too slow to perceive subjectively.

This article is intended for patients living with vitiligo and the dermatologists who treat them. It is based on published clinical literature and is not a substitute for individualised medical advice. Treatment outcomes vary by individual.